Jefferies Reports a Positive Turn in European Opinions on Revlimid Maintenance

According to a recent report from Jefferies, after speaking with 11 hematologists at the EHA meeting in London, Jefferies believes that the opinion of European physicians has turned positive on Revlimid maintenance and Celgene (NASDAQ: CELG).

In the report, Jefferies said, "Of the 11 hematologists who discussed their hypothetical use of Revlimid in maintenance therapy for multiple myeloma, 10 expected they would use maintenance and one expected that he would not use Revlimid in maintenance therapy."

Celgene closed Friday at $58.30.